Back to discover
Disease
Acute-On-Chronic Liver Failure
Late-stage therapeutic developmentEmerging research
2
Publications
22
Clinical trials
2020
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2020-01-01Hepatology (Baltimore, Md.)
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
Research2018-04-10Journal of hepatology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
- Q3 2026F573 for Injection for the Treatment of Liver Injury/Failure : Randomized, Double-blind, Placebo-controlled Phase Ⅱa Clinical Trial
- Q3 2027Single-center, Prospective, Randomized Controlled Study of PT-MSCs Exosome Injection (Code: PT-MSCs-EVS-2023-1) in the Treatment of Chronic-to-acute Liver Failure
Major developments
Upcoming trial readoutImportant
Results expected Q3 20272026-02-13
Upcoming trial readoutImportant
Results expected Q3 20262025-11-19
Clinical MilestonesViewHide
Results expected
- 2026-02-13Single-center, Prospective, Randomized Controlled Study of PT-MSCs Exosome Injection (Code: PT-MSCs-EVS-2023-1) in the Treatment of Chronic-to-acute Liver FailureResults expected Q3 2027
- 2025-11-19F573 for Injection for the Treatment of Liver Injury/Failure : Randomized, Double-blind, Placebo-controlled Phase Ⅱa Clinical TrialResults expected Q3 2026
Recently completed
- 2026-05-31Efficacy and Safety of Allogeneic Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Patients With Acute-on-chronic Liver FailureCompleted
- 2025-12-31A Phase I Safety and Tolerability Dose Escalation Study of Micro-encapsulated Hepatocytes Intraperitoneal Transplantation Therapy for Adult Liver Failure Patients.Primary completion
- 2025-12-03A Phase 1, Open Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy SubjectsCompleted
Other updates
- 2025-10-15A Phase 2a, Open-label, Randomized, Controlled, Multi-center Proof of Concept Study to Assess the Efficacy, Safety, and Tolerability of VS-01 on Top of Standard of Care, Compared to Standard of Care Alone, in Adult Patients With Acute-on-chronic Liver Failure (ACLF)Terminated
- 2025-10-01The Safety and Efficacy of Mesenchymal Stem Cells-Derived Extracellular Vesicles (MSC-EV) in Acute/Acute-on-Chronic Liver Failure：a Prospective, Randomized, Controlled Clinical StudyWithdrawn
Activity timeline7
- 2026-05-31ClinicalEfficacy and Safety of Allogeneic Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Patients With Acute-on-chronic Liver FailureCompleted
- 2026-02-13ClinicalSingle-center, Prospective, Randomized Controlled Study of PT-MSCs Exosome Injection (Code: PT-MSCs-EVS-2023-1) in the Treatment of Chronic-to-acute Liver FailureResults expected Q3 2027
- 2025-12-31ClinicalA Phase I Safety and Tolerability Dose Escalation Study of Micro-encapsulated Hepatocytes Intraperitoneal Transplantation Therapy for Adult Liver Failure Patients.Primary completion
- 2025-12-03ClinicalA Phase 1, Open Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy SubjectsCompleted
- 2025-11-19ClinicalF573 for Injection for the Treatment of Liver Injury/Failure : Randomized, Double-blind, Placebo-controlled Phase Ⅱa Clinical TrialResults expected Q3 2026
- 2025-10-15ClinicalA Phase 2a, Open-label, Randomized, Controlled, Multi-center Proof of Concept Study to Assess the Efficacy, Safety, and Tolerability of VS-01 on Top of Standard of Care, Compared to Standard of Care Alone, in Adult Patients With Acute-on-chronic Liver Failure (ACLF)Terminated
- 2025-10-01ClinicalThe Safety and Efficacy of Mesenchymal Stem Cells-Derived Extracellular Vesicles (MSC-EV) in Acute/Acute-on-Chronic Liver Failure：a Prospective, Randomized, Controlled Clinical StudyWithdrawn
Clinical trials
The current development programme across all trial phases.
Clinical programme
22
5
1
6
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20182020
Most influential
Major themes3
- Acute-On-Chronic Liver Failure1
- Gastroenterology1
- Liver Cirrhosis1
Leading journals2
- Hepatology (Baltimore, Md.)1
- Journal of hepatology1
Leading researchers5
- Crabb DW1
- Im GY1
- Lucey MR1
- Mellinger JL1
- Szabo G1
Affiliations (unnormalised)5
- Icahn School of Medicine at Mount Sinai1
- Indiana University School of Medicine1
- University of Massachusetts Medical School1
- University of Michigan Hospitals & Health Centers1
- University of Wisconsin School of Medicine1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Sudden liver failure in the presence of underlying compensated chronic LIVER DISEASE (e.g., LIVER CIRRHOSIS; HEPATITIS; and liver injury and failure) due to a precipitating acute hepatic insult.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.